Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From argenx N.V.
The Danish biotech has dipped its toe into co-commercialization recently and is seeking more candidates that are getting closer to the market.
Analysts said full data from the VIVACITY study in generalized myasthenia gravis would be key to determining the drug’s competitive profile against approved anti-FcRn agents.
To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.
The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.
- Large Molecule
- Other Names / Subsidiaries
- arGEN-X N.V.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.